Call for comments is now closed
Thank you to everyone who contributed to the Zika Virus Research and Development (R&D) Roadmap public review and comment period between 26 February through 16 April 2021. The roadmap development team appreciates the time and thought everyone gave to their comments. The roadmap is now being updated based on the feedback received.
The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, the University of Texas Medical Branch (UTMB), an expert team of taskforce members from around the world, and the World Health Organization (WHO) have developed
a draft Zika virus (ZIKV) Research and Development (R&D) Roadmap. The roadmap is a key component of the WHO’s R&D Blueprint, a global strategy
and preparedness plan that allows the activation of R&D activities in advance of and during epidemics.
The purpose of the roadmap is to accelerate the development and implementation of effective medical countermeasures for ZIKV aimed at reducing morbidity, mortality, and transmission. The roadmap identifies the vision, strategic goals, and aligned milestones
aimed at developing effective diagnostics, therapeutic agents, and vaccines for ZIKV.
Please provide comments following the instructions below. Kindly note that you can either provide input on the entire document or only on certain parts. Comments may be publicly disclosed at a later stage of the review process; submission of comments
will be considered as permission to publicly disclose feedback received. Comments should be submitted in English. Input received from this consultation will contribute to the further development and finalization of the roadmap.
Instructions for providing comments:
- The draft roadmap has line numbers to help align comments with specific sections.
- Submit your comments on the draft roadmap using this online form.
- The online form has three sections:
- Section 1: Your contact information. This is to document participation in the review process and to enable us to reach you if we need clarification on your comments.
- Section 2: General comments on the draft roadmap. There are 2 general questions (optional) about the draft roadmap. If you have no further comments, you can confirm that you have read the roadmap and have
no additional feedback (you can complete the review by selecting “no” when prompted in this section).
You will not be able to revise your responses to Section 1 or Section 2 once you move on to Section 3.
- Section 3: Section-specific review. You will have the opportunity to comment on each of the 5 topic-specific sections of the draft roadmap. A table of contents is available to facilitate your review of the sections. You may select individual sections for comment.
- If you are commenting on a specific part of the roadmap please include the line number(s) for reference.
- Please submit comments no later than Friday, 16 April 202.
If you have questions on the roadmap or public comment period, please email Ms. Virginia Benassi (benassiv@who.int) with the subject line “Zika virus R&D Roadmap.”